TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ophthalmological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality rates within 12 months
Endpoint domain: Mortality/survival
Primary endpoint: percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3/4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Growth of granulation tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALS competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Predictive Value (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vigilance scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Surgical errors
Endpoint domain: Adverse events/effects
Primary endpoint: NLF Severity Scale responder rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean patient-reported FACE-Q scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient satisfaction with treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incremental cost-effectiveness ratio (ICER) per QALY
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: iHOT-33 improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HOS sport subscale improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: All-cause mortality at six months
Endpoint domain: Mortality/survival
Primary endpoint: Composite endpoint of death, cardiogenic shock or new or worsening heart failure at six months
Endpoint domain: Mortality/survival
Primary endpoint: mean localization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of C‐arm fluoroscopy use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stopping azathioprine due to an adverse reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Obesity decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IgE level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Baseline prolactin (PRL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prolactin response to the infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Knowledge scores on postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge scores on neonatal resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-confidence scores on essential BEmONC procedures
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean phosphatemia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 7-day point-prevalence abstinence rate
Endpoint domain: Mortality/survival
Primary endpoint: reduced anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvements in perceived health and well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improved eccentric T/Bm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improved W/Bm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decreased EMG activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: overall incidence of air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: duration of air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: procedure costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mammogram receipt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Papanicolaou test receipt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Both tests receipt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in temporal fossa hollowness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to full functional ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in periodontal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time used on clinical treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to cuirass application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Failure rate of cuirass application
Endpoint domain: Adverse events/effects
Primary endpoint: VAS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of Constant‐Murley scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic effective rate
Endpoint domain: Mortality/survival
Primary endpoint: Stimulation of glucose disposal by high-dose insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suppression of nonesterified fatty acids by insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body fat increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HAQ disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in emotional health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Core body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Run duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative stress index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in episiotomy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Higher likelihood of having an intact perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction in third and fourth degree tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percentage reduction in LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: development of diabetes
Endpoint domain: Adverse events/effects
Primary endpoint: Mean itch intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD63 positive basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reported anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: perceived pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of urinary incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Voided volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in fine lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in appearance perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in carotenoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Disability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emesis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: return to normal diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise-induced QTd
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression to End-Stage Renal Disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Age differences in relationships
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Countermovement Jump (CMJ) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sprint Sit-up Performance Test (SSPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of cells expressing HLA-DR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of drug-related superficial punctate keratitis
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time spent in active pushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of thromboembolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: INR levels in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of phenylephrine required
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: variance of systolic blood pressure outside the desired range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of postoperative electrocardiogram or myocardial enzyme changes suggesting myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurodevelopmental outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: head circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSDI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Goblet cell density (GCD) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blepharospasm severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: overall light sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean blink rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intubating conditions at 60 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean times to reappearance of T3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse experiences related to rapacuronium
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Episodes of arterial oxygen saturation less than 90%
Endpoint domain: Adverse events/effects
Primary endpoint: Pain on injection
Endpoint domain: Adverse events/effects
Primary endpoint: Functional entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-domain entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality-adjusted life-year (QALY)
Endpoint domain: Resource use
Primary endpoint: relapse-free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Consistency in making trade-offs involving risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Short Physical Performance Battery score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean EBACFU0-7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographic in‐stent late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasmatic levels of TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasmatic levels of IL‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasmatic levels of high sensitive CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose escalation to the primary tumour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean percentage change in PASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Surface luster
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal staining of resin composites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: forward movement of the mandibular dentoalveolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ameliorating aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death from breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of long-lasting PSN
Endpoint domain: Adverse events/effects
Primary endpoint: Infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean marginal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PPD (Probing Pocket Depth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean BOP (Bleeding on Probing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with postvaccination hSBA ≥ 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ramsay sedation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in new vertebral and nonvertebral fracture incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: increase in lumbar spine bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: preservation of femoral neck density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean ocular perfusion pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: locoregional control
Endpoint domain: Mortality/survival
Primary endpoint: estimated leak rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fiber diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak systolic strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reliability of Humphrey visual fields
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fixation loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: False-negative error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rates of angina pectoris
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: DAS28 remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic nonprogression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration of naringenin and hesperetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Repeat revascularization procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SAF-scoring (steatosis, activity, fibrosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrent infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adoption of desired behavioural changes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of chemical cystitis
Endpoint domain: Adverse events/effects
Primary endpoint: cell death rates
Endpoint domain: Mortality/survival
Primary endpoint: Patients remaining with CCS class III or IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for bypass surgery (CABG)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients without reinterventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 3-years overall survival rate
Endpoint domain: Mortality/survival
Primary endpoint: 3-years disease-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: rate of local recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: operation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D₂ occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in Hb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of Lp-PLA2 mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of oxy-LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vo(2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔFEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total fentanyl patient‐controlled analgesia consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 mental component summary scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-36 general health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NBS or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of NBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overall survival at 36 months
Endpoint domain: Mortality/survival
Primary endpoint: Actuarial risk of relapse at 36 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time for relief of clinical symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall effectiveness rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center for Epidemiological Studies Depression (CESD) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiver Strain Index (CSI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insulin dosage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Graft survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of biopsy-proven acute rejection (AR)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in the percentage of S. sobrinus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number and severity of caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in lesion depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hr glucose nonresponders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes